Prophase Labs (PRPH) Q2 2024 earnings summary

Executive summary

• Q2 2024 marked a transformative period with strategic initiatives across all subsidiaries, including Pharmaloz's customer base expansion, new production lines, and exploration of a potential sale, as well as Nebula Genomics' DTC product revamp and BE-Smart Esophageal Cancer Test's commercialization progress.

• Net revenue for Q2 2024 was $2.5M, down from $13.2M in Q2 2023, driven by a sharp decline in diagnostic services and consumer products revenue due to reduced COVID-19 testing volumes.

• Net loss for Q2 2024 was $6.2M ($0.33/share) compared to $3.4M ($0.20/share) in Q2 2023; gross margin turned negative at (19.2)% for Q2 2024, reflecting the absence of diagnostic testing revenue and lower consumer product margins.

• Equivir supplement launch is imminent, supported by strong clinical results and robust retail interest, with final trial data expected in September.

• The company is not currently providing diagnostic testing services but remains prepared to scale up if demand returns.

Financial highlights

• Q2 2024 revenue: $2.5M (Q2 2023: $13.2M); six-month revenue: $6.1M (2023: $32.5M).

• Q2 2024 gross loss: $0.5M (Q2 2023: gross profit $6.4M); six-month gross loss: $0.9M (2023: gross profit $17.0M).

• Q2 2024 operating loss: $7.8M (Q2 2023: $4.7M); six-month operating loss: $16.1M (2023: $3.8M).

• Cash and equivalents at June 30, 2024: $2.4M; working capital: $16.1M (down from $26.7M at year-end 2023).

• Adjusted EBITDA for Q2 2024: $(5.3)M; Q2 2023: $(2.2)M.

Outlook and guidance

• Management anticipates significant sequential revenue and EBITDA growth in H2 2024, driven by new product launches and strategic initiatives, with Pharmaloz projecting $14–16M in revenue and over $5M in pre-tax profit for Q3 2024–Q2 2025.

• Nebula Genomics expects a new sales ramp in Q4 2024 following the DTC launch and rebranding.

• Equivir final trial data expected in September, with commercialization preparations underway.

• Sufficient liquidity is projected for at least 12 months, but future growth depends on new business lines and timely accounts receivable collection.

• The company is prepared to resume diagnostic testing if COVID-19 demand returns and is pursuing new product and acquisition opportunities.